Sionna Therapeutics Reports First Quarter 2026 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Guggenheim on Sionna Therapeutics (SION): 'We think these readouts are highly meaningful catalysts for the company'
May 12, 2026 12:20 PM EDTGuggenheim analyst Yatin Suneja reiterated a Buy rating and $50.00 price target on Sionna Therapeutics (NASDAQ: SION).
The analyst comments "This morning, SION announced 1Q26 earnings. The company ended 1Q26 with $289.9MM in cash and guided cash runway until 2028. Key updates are: (1) Phase IIa PreciSION study (n~16) has recently completed patient enrollment, and the company has reiterated topline readout guidance for summer 2026 (we think around... More
